Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Total Current Liabilities (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Total Current Liabilities data on record, last reported at $6.4 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 9.56% year-over-year to $6.4 million; the TTM value through Sep 2025 reached $6.4 million, up 9.56%, while the annual FY2024 figure was $10.0 million, 81.87% up from the prior year.
  • Total Current Liabilities reached $6.4 million in Q3 2025 per CTNM's latest filing, down from $7.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $10.0 million in Q4 2024 and bottomed at $3.7 million in Q2 2024.
  • Average Total Current Liabilities over 3 years is $6.7 million, with a median of $6.3 million recorded in 2024.
  • The widest YoY moves for Total Current Liabilities: up 92.94% in 2025, down 9.56% in 2025.
  • A 3-year view of Total Current Liabilities shows it stood at $5.5 million in 2023, then soared by 81.87% to $10.0 million in 2024, then crashed by 36.22% to $6.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $6.4 million in Q3 2025, $7.2 million in Q2 2025, and $8.9 million in Q1 2025.